Abstract
Background: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated serum enzyme that protects lipoproteins from oxidative modifications. Polymorphisms in the gene, including PON1Q192R, have been studied. However, inconsistencies regarding the above-mentioned polymorphism obscure its association with vascular disease.
Methods: Using a two-substrate (paraoxon/diazoxon) activity method, we investigated the frequencies of PON1Q192R phenotypes in 261 middle-aged subjects: 156 patients with angiographically assessed coronary heart disease (CHD) and 105 CHD-free subjects as the control group. The PON1192 phenotype was predicted from examination of the two-dimensional plot of hydrolysis rates of diazoxon vs. paraoxon and by using the antimode of the histogram of the ratio of diazoxonase/paraoxonase activity.
Results: The PON1Q192R phenotype frequencies in 113 patients with occlusion >50% (coronary artery disease-positive, CAD+ group) vs. control population were as follows: QQ (0.552 vs. 0.510), QR (0.382 vs. 0.408) and RR (0.066 vs. 0.082); χ2=0.414, p=0.813. We found lower paraoxonase (POase) and diazoxonase (DZOase) activities in the CAD+ patients when compared to the control population. According to logistic regression analysis, POase activity was a better predictor of coronary disease onset compared with DZOase activity measurements and PON1Q192R phenotyping.
Conclusions: We conclude that enzyme activity (within a particular phenotypic group) is more important than phenotype alone in predicting susceptibility to coronary artery disease.
Clin Chem Lab Med 2006;44:1206–13.
References
1. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Rad Biol Med 2005; 38:153–63.10.1016/j.freeradbiomed.2004.09.035Search in Google Scholar
2. Durrington PN, Mackness MJ. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:473–80.10.1161/01.ATV.21.4.473Search in Google Scholar
3. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101:2510–7.10.1161/01.CIR.101.21.2510Search in Google Scholar
4. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2 and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46:1239–47.10.1194/jlr.M400511-JLR200Search in Google Scholar
5. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln–Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346:869–72.10.1016/S0140-6736(95)92709-3Search in Google Scholar
6. Scmidt H, Schmidt R, Niederkorn K, Gradert A, Schumacher M, Watzinger N, et al. Paraoxonase PON1 polymorphism Leu–Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 1998; 29:2043–8.10.1161/01.STR.29.10.2043Search in Google Scholar
7. Akhmedova SN, Yakimovsky AK, Schwartz EI. Paraoxonase 1 Met–Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci 2001; 184:179–82.10.1016/S0022-510X(01)00439-7Search in Google Scholar
8. Primo-Parmo SL, Sorensen RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33:498–507.10.1006/geno.1996.0225Search in Google Scholar PubMed
9. Davis H, Richter RJ, Keifer M, Broomfield C, Sowalla J, Furlong CE. The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14:334–6.10.1038/ng1196-334Search in Google Scholar PubMed
10. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96:3005–8.10.1172/JCI118373Search in Google Scholar PubMed PubMed Central
11. Humbert R, Adler DA, Disteche CM, Hasset C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3:73–6.10.1038/ng0193-73Search in Google Scholar
12. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshimo H, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17:3565–9.10.1161/01.ATV.17.12.3565Search in Google Scholar
13. Sanghera D, Saha N, Aston CE, Kamboh MI. DNA polymorphism in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998; 62:36–44.10.1086/301669Search in Google Scholar
14. Pati N, Pati U. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol 1998; 66:165–8.10.1016/S0167-5273(98)00209-5Search in Google Scholar
15. Antikainen M, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, et al. The Gln–Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98:833–5.10.1172/JCI118869Search in Google Scholar
16. Rice G, Ossei-Gerning N, Stickland MH, Grant PJ. The paraoxonase Gln–Arg 192 polymorphism in subjects with ischemic heart disease. Coron Artery Dis 1997; 8:677–82.10.1097/00019501-199711000-00001Search in Google Scholar
17. Suehiro H, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, et al. Paraoxonase gene polymorphism in a Japanese subject with coronary heart disease. Int J Cardiol 1996; 57:69–73.10.1016/S0167-5273(96)02779-9Search in Google Scholar
18. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The Gln–Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998; 18:1611–6.10.1161/01.ATV.18.10.1611Search in Google Scholar
19. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86:193–9.10.1016/0021-9150(91)90215-OSearch in Google Scholar
20. Mackness B, Durrington P, McElduff P, Yarnel J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107:2775–9.10.1161/01.CIR.0000070954.00271.13Search in Google Scholar PubMed
21. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jumpsa R, Brophy VH, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003; 23:1465–71.10.1161/01.ATV.0000081635.96290.D3Search in Google Scholar
22. Causes of deaths. In: Vukomirovic D, editor. Statistical yearbook of Serbia 2005. Belgrade, Serbia: Statistical Office of the Republic of Serbia, 2005:90.Search in Google Scholar
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486–97.10.1001/jama.285.19.2486Search in Google Scholar
24. Richter R, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9:745–53.10.1097/00008571-199912000-00009Search in Google Scholar
25. Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet 1983; 35:393–408.Search in Google Scholar
26. Adkins S, Gan KN, Mody M, LaDu BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase; glutamine or arginine at position 191, for respective A or B allozymes. Am J Hum Genet 1993; 52:598–608.Search in Google Scholar
27. Girotti MJ, Khan N, McLellan BA. Early measurement of systemic lipid peroxidation products in plasma of major blunt trauma patients. J Trauma 1991; 31:32–5.10.1097/00005373-199101000-00007Search in Google Scholar
28. Bland JM, Altman DG. Statistics notes: transformations, means and confidence intervals. Br Med J 1996; 312:1079.10.1136/bmj.312.7038.1079Search in Google Scholar
29. McElveen J, Mackness MI, Colley M, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32:671–3.10.1093/clinchem/32.4.671Search in Google Scholar
30. Jarvik GP, Rozek LS, Brophy VH, Hatsukami T, Richter RJ, Shellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441–7.10.1161/01.ATV.20.11.2441Search in Google Scholar
31. Azarsiz E, Kayikcioglu M, Payzin S, Sozmen EY. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 2003; 91:43–51.10.1016/S0167-5273(02)00595-8Search in Google Scholar
32. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 2005; 16:393–9.10.1097/01.mol.0000174398.84185.0fSearch in Google Scholar PubMed
33. Blatter Garin MC, Abbott C, Messner S, Mackness M, Durington P, Pomette D, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994; 304:549–54.10.1042/bj3040549Search in Google Scholar PubMed PubMed Central
34. Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE. Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. In: Maines MD, Costa LG, Hodgson E, Reed DJ, Sipes IG, editors. Current protocols in toxicology. John Wiley & Sons, 2003:12–9.10.1002/0471140856.tx0412s19Search in Google Scholar
35. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier ChL, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 1999; 26:892–904.10.1016/S0891-5849(98)00272-XSearch in Google Scholar
36. Cao H, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 1999; 40:133–9.10.1016/S0022-2275(20)33348-4Search in Google Scholar
37. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630–39.10.1172/JCI118589Search in Google Scholar PubMed PubMed Central
38. La Du BN. Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23:1317–8.10.1161/01.ATV.0000082600.42562.7FSearch in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
